Lanvin Group Holdings Limited (LANV)
NYSE: LANV · Real-Time Price · USD
2.180
+0.070 (3.32%)
Mar 14, 2025, 4:00 PM EST - Market closed
Lanvin Group Revenue
Lanvin Group had revenue of 170.98M EUR in the half year ending June 30, 2024, a decrease of -15.23%. This brings the company's revenue in the last twelve months to 382.62M, down -12.07% year-over-year. In the year 2023, Lanvin Group had annual revenue of 426.18M with 0.92% growth.
Revenue (ttm)
382.62M EUR
Revenue Growth
-12.07%
P/S Ratio
0.62
Revenue / Employee
145,096 EUR
Employees
2,637
Market Cap
255.76M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 426.18M | 3.87M | 0.92% |
Dec 31, 2022 | 422.31M | 113.49M | 36.75% |
Dec 31, 2021 | 308.82M | 86.21M | 38.73% |
Dec 31, 2020 | 222.61M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLANV News
- 10 days ago - PharmaEssentia Highlights Availability of BESREMi® (ropeginterferon alfa-2b-njft) for Patients Affected by Pegasys® (peginterferon alfa-2a) Drug Shortage - Business Wire
- 14 days ago - Lanvin Group Holdings Limited (LANV) 2024 Sales/Trading Statement Call Transcript - Seeking Alpha
- 14 days ago - Lanvin Group Prioritizes Creative Renewal and Operational Agility Amid Evolving Luxury Landscape - PRNewsWire
- 26 days ago - Lanvin Group to Report 2024 Full-Year Preliminary Revenues on February 28, 2025 - PRNewsWire
- 2 months ago - Lanvin Group Announces Leadership and Board Changes to Accelerate Growth and Strategic Initiatives - PRNewsWire
- 2 months ago - PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia - Business Wire
- 4 months ago - Lanvin Group Holdings Limited to Hold Annual General Meeting on December 11, 2024 - PRNewsWire
- 6 months ago - PharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to Commercialize BESREMi® (ropeginterferon alfa-2b-njft) in Canada - Business Wire